Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Jun 1:20:2839-2847.
doi: 10.1016/j.csbj.2022.05.057. eCollection 2022.

Drug repositioning in drug discovery of T2DM and repositioning potential of antidiabetic agents

Affiliations
Review

Drug repositioning in drug discovery of T2DM and repositioning potential of antidiabetic agents

Sha Zhu et al. Comput Struct Biotechnol J. .

Abstract

Repositioning or repurposing drugs account for a substantial part of entering approval pipeline drugs, which indicates that drug repositioning has huge market potential and value. Computational technologies such as machine learning methods have accelerated the process of drug repositioning in the last few decades years. The repositioning potential of type 2 diabetes mellitus (T2DM) drugs for various diseases such as cancer, neurodegenerative diseases, and cardiovascular diseases have been widely studied. Hence, the related summary about repurposing antidiabetic drugs is of great significance. In this review, we focus on the machine learning methods for the development of new T2DM drugs and give an overview of the repurposing potential of the existing antidiabetic agents.

Keywords: AD, Alzheimer’s Disease; AEs, autoencoders; ASCVD, atherosclerotic cardiovascular disease; Antidiabetic drugs; CNNs, convolutional neural networks; CV, cardiovascular; CVD, cardiovascular diseases; DBNs, deep brief networks; DDA, drug-disease association; DDI, drug-drug interaction; DL, deep learning; DM, diabetes mellitus; DNNs, deep neural networks; DPP-4, dipeptidyl peptidase 4; DTI, drug-target interaction; Deep learning; Drug repositioning; Drug repurposing; GLP-1, glucagon-like peptide 1; GNNs, graph neural networks; ML, machine learning; Machine learning; PD, Parkinson’s Disease; PI3K/AKT, phosphatidylinositol 3-kinase/AKT; RNNs, recurrent neural networks; SGLT-2, sodium-glucose cotransporter 2; T2DM; T2DM, type 2 diabetes mellitus; TZD, thiazolidinedione; cAMP/PKA, cyclic adenosine monophosphate/protein kinase A.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Figures

Fig. 1
Fig. 1
Schematic diagram of T2DM. It shows the high-risk factors, complications, and management of T2DM.
Fig. 2
Fig. 2
The machine learning methods for drug-disease pairs prediction in drug repositioning. DTI: drug-target interaction, DDI: drug-drug interaction, DDA: drug-disease association, DBN: deep belief network, CNN: convolutional neural network, DNN: deep neural network, RNN: recurrent neural network, FNN: feedforward neural network, GNN: graph neural network, AE: autoencoder.

Similar articles

Cited by

References

    1. Ashburn T.T., Thor K.B. Drug repositioning: identifying and developing new uses for existing drugs. Nat Rev Drug Discov. 2004;3(8):673–683. - PubMed
    1. Langedijk J., et al. Drug repositioning and repurposing: terminology and definitions in literature. Drug Discov Today. 2015;20(8):1027–1034. - PubMed
    1. Jourdan J.P., et al. Drug repositioning: a brief overview. J Pharm Pharmacol. 2020;72(9):1145–1151. - PMC - PubMed
    1. Oprea T.I., et al. Drug Repurposing from an Academic Perspective. Drug Discov Today Ther Strateg. 2011;8(3–4):61–69. - PMC - PubMed
    1. Bertolini F., Sukhatme V.P., Bouche G. Drug repurposing in oncology–patient and health systems opportunities. Nat Rev Clin Oncol. 2015;12(12):732–742. - PubMed

LinkOut - more resources